Dyadic International

Dyadic International, Inc. is a global biotechnology company headquartered in Jupiter, FL, with operations in the United States and Europe. With a rich history dating back to 1979, Dyadic has evolved into a leading life sciences company, specializing in the development of microbial platforms for industrial enzymes, human and animal pharmaceuticals, and alternative proteins. Their proprietary C1 platform, based on the Thermothelomyces heterothallica fungus, enables the cost-effective production of commercial quantities of proteins and enzymes, while their Dapibus platform is engineered to address global shortfalls in protein production for non-pharmaceutical applications. Dyadic is committed to revolutionizing science, medicine, agriculture, and engineering to improve global health and sustainability.

With decades of experience in industrial-scale biomanufacturing, Dyadic has established itself as a trusted partner for leading biopharmaceutical and bioindustrial companies worldwide. Their versatile gene expression system, the C1 platform, is being used to develop and manufacture vaccines, antibodies, and other therapeutic treatments to meet the growing demand for preventative and therapeutic biopharmaceuticals. Additionally, Dyadic's innovative microbial platforms are addressing the global protein bioproduction needs for human and animal health, as well as alternative proteins for food, nutrition, and wellness. Through their cutting-edge technology and strategic partnerships, Dyadic is at the forefront of advancing biotechnology to feed, fuel, and heal the global population.

Generated from the website